PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Abstract Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoon Jin Cha, Dooreh Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong, Hye Sun Lee, Soyoung Jeon, Tae-Kyung Yoo, Woo-Chan Park, Chang Ik Yoon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0597b8278dd9439abf128006ae1c2932
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0597b8278dd9439abf128006ae1c2932
record_format	dspace
spelling	oai:doaj.org-article:0597b8278dd9439abf128006ae1c29322021-12-02T17:17:40ZPD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection10.1038/s41598-021-97250-22045-2322https://doaj.org/article/0597b8278dd9439abf128006ae1c29322021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97250-2https://doaj.org/toc/2045-2322Abstract Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) analysis. We retrospectively investigated tumor tissues derived from 316 breast cancer cases, by constructing tissue microarrays and by performing IHC staining. The immune-cell expression rate (for SP142 and SP263) and combined proportional score (for 22C3) were evaluated, and survival outcomes were analyzed. Prediction models were developed, and values of Harrel’s c-index and areas under curves were calculated to compare the discriminatory power. Negative PD-L1 expression based on the 22C3-IHC assay was determined to be an independent prognostic marker for recurrence-free survival (RFS, P = 0.0337) and distant metastasis-free survival (DMFS, P = 0.0131). However, PD-L1 expression based on SP142- and SP263-IHC assays did not reveal a prognostic impact. Among the three antibodies, adding PD-L1 expression data obtained via 22C3-IHC assay to the null model led to a significant improvement in the discriminatory power of RFS and DMFS. We suggest that PD-L1 expression based on the 22C3-IHC assay is a superior prognostic marker than that based on SP142- and SP263-IHC assays.Yoon Jin ChaDooreh KimSoong June BaeSung Gwe AhnJoon JeongHye Sun LeeSoyoung JeonTae-Kyung YooWoo-Chan ParkChang Ik YoonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yoon Jin Cha Dooreh Kim Soong June Bae Sung Gwe Ahn Joon Jeong Hye Sun Lee Soyoung Jeon Tae-Kyung Yoo Woo-Chan Park Chang Ik Yoon PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
description	Abstract Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) analysis. We retrospectively investigated tumor tissues derived from 316 breast cancer cases, by constructing tissue microarrays and by performing IHC staining. The immune-cell expression rate (for SP142 and SP263) and combined proportional score (for 22C3) were evaluated, and survival outcomes were analyzed. Prediction models were developed, and values of Harrel’s c-index and areas under curves were calculated to compare the discriminatory power. Negative PD-L1 expression based on the 22C3-IHC assay was determined to be an independent prognostic marker for recurrence-free survival (RFS, P = 0.0337) and distant metastasis-free survival (DMFS, P = 0.0131). However, PD-L1 expression based on SP142- and SP263-IHC assays did not reveal a prognostic impact. Among the three antibodies, adding PD-L1 expression data obtained via 22C3-IHC assay to the null model led to a significant improvement in the discriminatory power of RFS and DMFS. We suggest that PD-L1 expression based on the 22C3-IHC assay is a superior prognostic marker than that based on SP142- and SP263-IHC assays.
format	article
author	Yoon Jin Cha Dooreh Kim Soong June Bae Sung Gwe Ahn Joon Jeong Hye Sun Lee Soyoung Jeon Tae-Kyung Yoo Woo-Chan Park Chang Ik Yoon
author_facet	Yoon Jin Cha Dooreh Kim Soong June Bae Sung Gwe Ahn Joon Jeong Hye Sun Lee Soyoung Jeon Tae-Kyung Yoo Woo-Chan Park Chang Ik Yoon
author_sort	Yoon Jin Cha
title	PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
title_short	PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
title_full	PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
title_fullStr	PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
title_full_unstemmed	PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
title_sort	pd-l1 expression evaluated by 22c3 antibody is a better prognostic marker than sp142/sp263 antibodies in breast cancer patients after resection
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0597b8278dd9439abf128006ae1c2932
work_keys_str_mv	AT yoonjincha pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT doorehkim pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT soongjunebae pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT sunggweahn pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT joonjeong pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT hyesunlee pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT soyoungjeon pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT taekyungyoo pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT woochanpark pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection AT changikyoon pdl1expressionevaluatedby22c3antibodyisabetterprognosticmarkerthansp142sp263antibodiesinbreastcancerpatientsafterresection
_version_	1718381124639522816

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Ejemplares similares